HUTCHMED DRC
$ 15.30
0.59%
15 Apr - close price
- Market Cap 2,615,342,000 USD
- Current Price $ 15.30
- High / Low $ 15.43 / 15.00
- Stock P/E 5.74
- Book Value 7.20
- EPS 2.65
- Next Earning Report 2026-06-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.02 %
- ROE 0.45 %
- 52 Week High 19.50
- 52 Week Low 12.98
About
HUTCHMED (China) Limited discovers, develops and markets targeted immunotherapies and therapies for cancer and immune diseases globally. The company is headquartered in Central, Hong Kong.
Analyst Target Price
$22.85
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-23 | 2025-11-28 | 2025-08-07 | 2025-05-28 | 2025-03-19 | 2024-11-29 | 2024-07-31 | 2024-05-29 | 2024-02-28 | 2023-11-10 | 2023-07-31 | 2023-05-31 |
| Reported EPS | None | 0 | 0.52 | 0 | 0.01 | 0 | 0 | 0 | -0.7 | 0 | 0.97 | 0 |
| Estimated EPS | 0.25 | 0 | 0 | 0 | 0.04 | 0 | 0 | 0 | -1.08 | 0.04 | -0.055 | -0.05 |
| Surprise | 0 | 0 | 0.52 | 0 | -0.03 | 0 | 0 | 0 | 0.38 | -0.04 | 1.025 | 0.05 |
| Surprise Percentage | None% | None% | None% | None% | -75% | None% | None% | None% | 35.1852% | -100% | 1863.6364% | 100% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-06-04 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: HCM
2026-04-10 16:39:13
This article provides a comprehensive overview of HUTCHMED CHINA-ADR (NASDAQ:HCM) stock, including its current price, performance, financial statistics, and analyst forecasts. It details the company's technical and fundamental ratings from ChartMill, its earnings history, and its position within the healthcare sector and pharmaceuticals industry. The article also includes a company profile outlining its business segments and key operational details.
2026-04-09 10:09:27
HUTCHMED (China) Limited has announced its plans for the 2026 Annual General Meeting (AGM), scheduled for May 12, 2026, in a hybrid format. Key proposals for shareholder approval include the re-election of directors, a renewed mandate for the company to repurchase up to 10% of its issued shares, and the adoption of a new 2026 Share Option Scheme. This new scheme would allow for options over up to 5% of the company’s issued share capital, featuring a 10-year option life, a minimum 12-month vesting period, and performance conditions.
2026-04-09 10:09:27
HUTCHMED (HCM) will present new and updated oncology research data at the AACR Annual Meeting 2026, featuring its antibody-targeted therapy conjugate (ATTC) platform, specifically preclinical data for HMPL-A580, and updated clinical data for surufatinib in combination regimens for gastrointestinal cancers. HMPL-A580 is a first-in-class PI3K/PIKK-EGFR ATTC demonstrating potent kinase inhibition and anti-tumor effects in preclinical models. Clinical updates for surufatinib include trials for metastatic small bowel and appendiceal cancers, and pancreatic ductal adenocarcinoma.
2026-04-09 03:39:01
HUTCHMED (00013.HK) has announced that new and updated data from several studies involving compounds discovered by the company will be presented at the American Association of Cancer Research (AACR) Annual Meeting in 2026. The AACR meeting is scheduled to take place from April 17-22, 2026, in San Diego, California.
2026-04-09 01:09:27
HUTCHMED will present new and updated data from several studies of compounds discovered by the company at the American Association of Cancer Research (AACR) Annual Meeting 2026. The meeting is scheduled to take place from April 17-22, 2026, in San Diego, California. The announcement highlights ongoing research and development efforts by HUTCHMED in the field of cancer treatment.
2026-04-08 23:40:16
HUTCHMED will present new preclinical data for its first-in-class HMPL-A580, an EGFR-targeted Antibody-Targeted Therapy Conjugate (ATTC), at the AACR Annual Meeting 2026. The data show potent PI3K/PIKK inhibition and dose-dependent anti-tumor activity in preclinical models. Additionally, updated clinical data from investigator-initiated Phase Ib/II and exploratory Phase II studies of surufatinib combinations for various cancers will be presented.
